A Phase II Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC

NCT04736823 Phase 2 ACTIVE_NOT_RECRUITING

This is a phase II study. All patients are stage IIIB/C or IV non-small cell lung cancer(NSCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1. The purpose of this study is to evaluate the efficacy and safety of AK112 in combination with chemotherapy in patients with NSCLC.

Details

Lead sponsor	Akeso
Phase	Phase 2
Status	ACTIVE_NOT_RECRUITING
Enrolment	265
Start date	2021-02-01
Completion	2026-12

Conditions

• NSCLC

Interventions

• AK112
• Pemetrexed
• Paclitaxel
• Carboplatin
• Docetaxel

Primary outcomes

• ORR — Up to approximately 2 years
  ORR is the proportion of subjects with CR or PR , based on RECIST v1.1.

Countries

China